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elderly population. These results confirm that immunizing transplant patients
against influenza remains a challenge and requires new strategies to be ex-
plored (dose increase, additional injections, intradermal route).
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Background: Infection remains a source of mortality in heart recipients. We
assessed whether monitoring of NK-cells could prove useful when identifying
patients at risk of infection.
Methods: We prospectively studied 133 consecutive heart recipients over
a 12-month period. Severe infections that required intravenous antimicrobial
therapy was the primary outcome. Superficial incisional surgical site infec-
tion, catheter-related infections were not considered infectious episodes in this
study. As for immunosuppressive treatment, patients received induction ther-
apy with the interleukin (IL) 2 receptor antagonist daclizumab (n=108 [93.1%])
or basiliximab (n=5 [4.3%]). Maintenance immunosuppression included my-
cophenolate mofetil, prednisone, and either cyclosporine (n=35, 30.2%) or
tacrolimus (n=79, 68.1%), depending on the side effects. Total counts and per-
centages of NK-lymphocyte subsets (CD3–CD56/CD16+) were analyzed by
four-color flow cytometry whole blood.
Results: Forty-eight patients had at least one episode of severe infection. Pa-
tients with severe infection (n=48) disclosed lower NK absolute counts (day-
7 after transplantation [28 vs 57, P=0.021]), 3 months [96 vs 168 cells/uL,
P=0.002], 6 months [127 vs 183 cells/uL, P=0.011] and 1 year [154 vs 254
cells/uL, P=0.014]). Patients with bacterial infections (n=27) disclosed lower
NK absolute counts (day-7 [22 vs 52 cells/uL, P=0.040]). Patients with CMV
infection (n=22) disclosed lower NK percentages (1 year [7 vs 14, P=0.006]),
lower NK-cell absolute counts (day-30 [80 vs 117 cells/uL, P=0.05], 3 months
[96 vs 151 cells/uL, P=0.016] and 1 year [133 vs 234 cells/uL, P=0.043]). In
Cox regression analysis we found an association between the risk of develop-
ing an infection and lower day-7 absolute NK-cell count (per decrease of 10
cells/uL, RH 1.24, P=0.011).
Conclusion: Data suggest that monitoring including NK-cell testing is useful
when attempting to identify the risk of infection in heart recipients.
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Background: Duration of retaining ureteric stent after kidney transplantation
was still controversy. Short duration of ureteric stent may reduce urinary tract
infection (UTI) after kidney transplantation. This study aims to determine ben-
efits and risks of early versus routine stent removal in kidney transplantation.
Methods: Single-center parallel randomized controlled, open label, trial. Ran-
domization was computer-generated block of 4, allocation concealment by
sealed opaque envelops. 80 patients who underwent kidney transplantation
at a University-based hospital in Thailand from April2010- January2011 were
enrolled. Patients were randomized to early ureteric stent removal (8 days) or
routine ureteric stent removal (15 days) after kidney transplantation. The pri-
mary outcome was rate of UTI during postoperative to 1 week after discharge.
Chi-square or Fisher’s exact was used to compare the proportion of UTI be-
tween groups.
Results: 65 patients (57% living donor) fulfilled the randomized criteria (early
remove n=32; routine remove n=33). By intention to treat analysis, incidence
of UTI in early stent removal was less than routine stent removal group
(12/32, 37.5% VS 24/33, 72.7%; Risk reduction 35.2%; 95%CI 12.5 to 57.8%,
P=0.004). The benefit of early ureteric stent removal is demonstrated mostly
in living donor subgroup. Incidence of UTI was significantly associated with the
duration of stent retention. Incidence of urologic complications was not differ-
ent in both groups.
Conclusions: Shortening the duration of ureteric stent in kidney transplant
recipients from 15 to 8 days is safe. This approach helps to reduce incidence
of UTI particularly in living kidney transplantation. (Funded by Thai Transplant
Society; Trial registration ACTRN12610000310066)
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Background: PTLD is a life-threatening complication of all types of transplan-
tation (Tx).
Methods/Materials: Retrospective analysis of medical records of all patients
diagnosed with PTLD between January 1989 and December 2010 at the Uni-
versity Hospitals of Leuven, aiming to obtain information about incidence, pre-
treatment characteristics, treatment and outcome.
Results: 140 biopsy proven PTLD cases were included. Overall incidence was
2%. Highest incidence was reported in heart-lung Tx (7.5%), followed by heart
(4.9%), lung (2.9%), liver (2.67%), stem cell (1.4%), kidney (1.3%) and intesti-
nal Tx (0%). Most PTLD were monomorphic (83.6%), with diffuse large B cell
lymphoma (DLBCL) being the most frequent subtype. 66.2% of the cases were
EBV positive. The majority of cases (70.7%) occurred > 1 year post-Tx. At
diagnosis immunosuppressive therapy included calcineurin inhibitors (92%),
antimetabolites (71%) and low dose steroids (71%). Reduction of immunosup-
pression (RIS) was performed in 88.5%. Other first line treatment modalities
included rituximab (53%), chemotherapy (28%), surgery (12%) and radiother-
apy (7%). Following first line therapy overall response rate was 68.5% (53.5
CR, 15% PR). At last follow up 43% of the patients were alive whereas 10.7%
of the patients lost their graft during follow up. In multivariate analysis higher
age at diagnosis, hypoalbuminemia and elevated LDH were associated with
poor overall survival.
Conclusion: Overall PTLD incidence was 2%. As expected most cases were
DLBCL, presented with advanced stage and had a poor outcome. 66.2% were
EBV positive. Except for RIS, treatment was very heterogeneous. Contrary to
data from the literature the majority of cases occurred late, whereas rituximab
therapy was not associated with higher response rates. Although the prog-
nostic role of the international prognostic index (IPI) score in PTLD has been
questioned, we were able to confirm its value in our analysis.
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Background: Donation after cardiac death (DCD) was (re)introduced in Bel-
gium in 2000 to expand the pool of kidney grafts. We reviewed the Belgian
experience of DCD kidney transplantation (KTx) and compared short and long
term graft and patient survival between machine perfusion (MP) and cold stor-
age (CS) preservation.
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Methods: We reviewed all DCD KTx performed in Belgium between 01/2000
and 12/2009. Donor and recipient data were collected from Eurotransplant and
all 6 Belgian KTx centers.
Results: During the study period, 287 DCD KTx were performed (13% of all
deceased KTx). Median follow up was 34 (8-130) months. Kidneys were stored
by CS (n=135) or MP (n=152). The incidence of delayed graft function (DGF)
was 10% lower in MP compared to CS kidneys (p=0.07), despite longer cold
ischemia time (CIT) [17.9 (4.30-30.8) h versus 13.8 (3.5-26.7) h; p<0.001))
and anastomotic time [34 (20-70) min versus 31 (11-71) min; p<0,001) and
more uncontrolled DCD donors (10.5% versus 3%) in MP kidneys. In multi-
variate analysis, MP reduced the risk of DGF (Odds ratio 0.30 (0.14-0,66);
p=0,003). CIT was also an independent risk factor of DGF (Odds ratio 1.14
(1.05-1.23);p<0.001). The 1, 3 and 5-year patient/censored graft survival were
comparable between MP and CS (97%, 96%, 92%/97%, 93%, 93% MP versus
96%, 92%, 81%/93%, 89%, 78% CS; log rank 0,06/0,20).
Conclusion: DCD KTx in Belgium is associated with excellent short and mid-
dle term results. In this Belgian patient cohort and in line with previous studies,
MP decreases the risk of development of DGF whereas CIT increases this
risk. In addition, our data strongly suggest that the impact of CIT on DGF is
reduced by MP.
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Background: There is a general reluctance to use kidneys from uncontrolled
donors after cardiac death (DCD) for transplantation because of the relatively
high incidence of primary non-function (PNF) and delayed graft function (DGF).
Therefore, we compared the initial and long-term graft function and the survival
of kidneys between uncontrolled and controlled DCD donors.
Methods: From January 1981 to January 2008, 523 DCD kidneys were pro-
cured in the Maastricht region of which 173 were discarded. 334 DCD kidneys
(128 uncontrolled and 206 controlled) were transplanted in the Eurotransplant
region and completed follow-up. We studied the short and long-term graft func-
tion and the graft survival after transplantation.
Results: The incidence of PNF and DGF in both uncontrolled and controlled
DCD kidneys is relatively high (PNF: 22% vs.21%, p = 0.81, and DGF: 79% vs.
71%, p = 0.20, respectively). Graft function assessed with estimated glomeru-
lar filtration rate (eGFR) at year 1 after transplantation is 40±16 vs. 42±19
mL/min/1.73m2 , p = 0.55, with a yearly decline thereafter of 0.67±3 vs. 0.70±7
mL/min/1.73m2 /year, p = 0.97. Furthermore, the long-term graft and recipient
survival at ten years after transplantation do not differ between uncontrolled
and controlled DCD kidneys: 52% vs. 46%, p = 0.68 and 61% vs. 60%, p =
0.76, respectively.
Conclusion: This study demonstrates that the initial function and long-term
outcome of uncontrolled DCD kidneys is comparable to the outcome of con-
trolled DCD kidneys. In both groups, careful selection of both donor kidneys
and recipients is mandatory to reduce the risk of PNF. These results justify
expansion of the donor pool with uncontrolled donors to reduce the still grow-
ing waiting list for renal transplantations and may stimulate implementation of
uncontrolled DCD kidney donation programmes.
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Kidney grafts from uncontrolled deceased donors after cardiac arrest (uDDCA)
have recently been used in France to counteract organ shortage. The quality
of these kidneys remains debatable. The aim of our study was to compare
the outcomes and the quality of uDDCA kidneys with that of kidneys from op-
timal donors such as simultaneous kidney and pancreas (SPK) donors and
extended-criteria donors (ECD).
27 kidney grafts from uDDCA (mean donor age, 41) were compared with 24
kidney grafts from SPK donors (mean donor age, 26), and 30 kidney grafts
from ECD (mean donor age, 66). All three patient groups were non-immunized
and received the same induction and maintenance immuossupressive therapy.
The quality of the grafts was assessed by renal function and histology. GFR
was estimated by MDRD formula (eGFR) at M1 (n=80), M3 (n=80), M6 (n=79),
M12 (n=74), M24 (n=70) and M36 (n=51) and measured by inuline clearance
(mGFR) at M12 (n=66) and M36 (n=46). Interstitial fibrosis (IF) and vascular
lesions were analyzed in systematic kidney biopsies at M3 (n=54) and M12
(n=50) with the Banff 2007 classification. IF was quantitatively measured by
colour image analysis.
Kidney graft quality from SPK group was always superior than the two others
groups. In the short term, DGF in the uDDCA group was significantly higher
than in the ECD group (Table 1).
Table 1. Early outcome
uDDCA ECD p uDDCA vs ECD
PNF (%) 0 0 NA
DGF (%) 81.5 27.6 <0.0001
Mean (sd) HD session 4.7 (3.9) 0.7 (1.4) <0.0001
Mean (sd) time of HD (days) 15.6 (13.0) 2.8 (5.9) <0.0001
Mean (sd) time of renal function recovery (days) 17.8 (9.2) 5.0 (5.2) <0.0001
Clinical rejetion n (%) 5 (18.5) 7 (23.3) 0.62
Subclinical rejection n (%) 2 (7.4) 3 (7.5) 0.71
Borderline changes n (%) 12 (44.4) 8 (26.6) 0.15
PNF = Primary non function, DGF = Delayed graft function, HD = Hemodialysis.
In the uDDCA group renal function was initially poorer but improved during the
first year.
However on the long term, renal function and interstitial fibrosis was not differ-
ent in uDDCA vs ECD group (Table 2).
Table 2. Kidney graft function and histology
Mean (sd) uDDCA ECD p uDDCA vs ECD
e GFR M1 23.4 (8.7) 40.2 (16.0) <0.001
e GFR M3 38.9 (11.7) 39.5 (17.0) 0.96
e GFR M6 41.7 (12.6) 41.5 (16.5) 0.88
e GFR M12 45.2 (13.0) 45.2 (15.4) 0.97
e GFR M24 45.2 (13.8) 45.0 (20.9) 0.97
e GFR M36 44.1 (14.1) 37.4 (10.4) 0.13
m GFR M12 44.3 (13.0) 40.2 (14.6) 0.31
m GFR M36 41.2 (12.3) 33.7 (11.2) 0.09
IF score M3 30% (9) 28% (12) 0.52
IF score M12 36% (13) 33% (14) 0.47
e GFR: estimated GFR accoring to simplified MDRD formula; m GFR: GFR measured by
inulin clearance; IF score: Intersitial fibrosis score obtained by colour image analysis.
Conclusion: Our study suggests that the quality of kidneys from uDDCA
donors is similar to that of ECD and that these kidneys should be attributed
to the same recipient population.
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Donation after Cardiac death (DCD) is becoming increasingly common and
provides kidneys with comparable outcome to heart-beating (DBD) kidneys.
Increasingly marginal DCD kidneys from elderly donors (60+) have been used
and long term outcomes are not yet known. Histopathological scoring systems
for marginal DBD kidneys based on the presence of chronic damage have not
been validated for DCD kidneys. Here we report how baseline damage impacts
on outcomes of DCD kidneys.
Outcomes of all first time and single-kidney DCD (213) and DBD (100) trans-
plants performed at our centre between 2006 and 2010 were analysed. Time
zero biopsies were performed routinely and were scored histopathologically
according to the presence of glomerular, tubular, parenchymal and vascular
disease (0-3 for each component) as described previously by Remuzzi et
al. Multivariate analysis was performed to assess the effect of a number of
donor variables (age, sex, type [DCD vs DBD], hypertension, smoking, cold
ischaemic time and HLA mismatch level) on outcome.
DCD kidneys scoring 4-6 had poorer graft survival than DCD kidneys scoring
0-3 though acceptable graft survival rates were achieved. DCD Kidneys with
donor age >55 and score 4-6 appear to have poorer graft survival with only
40% of grafts surviving past 3 years. Multiple regression analysis showed that
the effect of baseline score on outcome remained after controlling for donor
age (Table 1).
Table 1. Multiple regression analysis of donor age and global score vs 90 day eGFR
Variables (n=114) Range Estimate Standard Error P-value
Donor Age (years) 14– 82 –0.35 0.11 0.001
Global Score (0-12) 0–6 –2.00 1.00 0.047
